U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C2H4Cl3O2Te.H4N
Molecular Weight 312.05
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of AMMONIUM TRICHLOROTELLURATE

SMILES

[NH4+].Cl[Te-]1(Cl)(Cl)OCCO1

InChI

InChIKey=AXWLPMGUUAIGJK-UHFFFAOYSA-O
InChI=1S/C2H4Cl3O2Te.H3N/c3-8(4,5)6-1-2-7-8;/h1-2H2;1H3/q-1;/p+1

HIDE SMILES / InChI

Molecular Formula C2H4Cl3O2Te
Molecular Weight 294.01
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula H3N
Molecular Weight 17.0305
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Ammonium trichlorotellurate (AS-101) is a synthetic non-toxic tellurium derivative, structurally similar to cisplatin, with immunostimulatory and anti-hair loss properties. Ammonium trichlorotellurate induces production of colony stimulating factor (CSF), interleukin-2 (IL-2), and IL-2 receptors by increasing the calcium ion influx through the cell membrane and subsequently exerts its immunostimulatory effects through the CSF-mediated increase in macrophage/granulocytes. This agent is also a potent inducer of interferon and a spectrum of cytokines such as IL-1, IL-6, and tumor necrosis factor (TNF). In animal studies, ammonium trichlorotellurate exerts its anti-hair loss effect by inducing anagen and obstructing spontaneous catagen via promoting follicular keratinocyte proliferation and interfering with terminal differentiation, respectively. AS-101 suppresses production of HIV-1. It inhibited reverse transcriptase activity and replication of human immunodeficiency virus type 1. RDDP and DDDP activities were impaired by the drug with calculated IC50 value of about 4 uM. Intravenous AS-101 was in trials in patients with HIV infections. AS-101, a small-molecule integrin αvβ3 and VLA-4 inhibitor is being developed by BioMAS in Israel for the treatment of genital warts, age-related macular degeneration and fertility preservation. Phase II clinical trials are ongoing. The drug was also undergoing phase II development in acute myeloid leukaemia, atopic dermatitis, chemotherapy-induced damage, myelodysplastic syndromes, thrombocytopenia, alopecia, psoriasis. However, development for these indications was discontinued.

Approval Year

PubMed

PubMed

TitleDatePubMed
Toxicity study in rats of a tellurium based immunomodulating drug, AS-101: a potential drug for AIDS and cancer patients.
1989

Sample Use Guides

15% AS-101 ointment applied twice a day for treatment of external genital warts.
Route of Administration: Topical
Isolated rat glomerular macrophages were cultured with SAC (5 ug/ml) for 24 h. Cells were detached and cultured at 104/well in triplicates in the presence or absence of various AS-101 concentrations (0.05-1 ug/ml) for 1 h. Caspase-1 activity was evaluated. AS-101 significantly inhibited Caspase-1 activity in a dose-dependent manner.
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:39:44 GMT 2023
Edited
by admin
on Fri Dec 15 15:39:44 GMT 2023
Record UNII
708681952A
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
AMMONIUM TRICHLOROTELLURATE
Systematic Name English
AS-101
Code English
AMMONIUM TRICHLORO(DIOXYETHYLENE-O,O')TELLURIUM(IV)
Common Name English
AS101
Code English
OSSIRENE
Common Name English
Classification Tree Code System Code
FDA ORPHAN DRUG 22387
Created by admin on Fri Dec 15 15:39:44 GMT 2023 , Edited by admin on Fri Dec 15 15:39:44 GMT 2023
NCI_THESAURUS C2139
Created by admin on Fri Dec 15 15:39:44 GMT 2023 , Edited by admin on Fri Dec 15 15:39:44 GMT 2023
Code System Code Type Description
CAS
106566-58-9
Created by admin on Fri Dec 15 15:39:44 GMT 2023 , Edited by admin on Fri Dec 15 15:39:44 GMT 2023
PRIMARY
NCI_THESAURUS
C1006
Created by admin on Fri Dec 15 15:39:44 GMT 2023 , Edited by admin on Fri Dec 15 15:39:44 GMT 2023
PRIMARY
FDA UNII
708681952A
Created by admin on Fri Dec 15 15:39:44 GMT 2023 , Edited by admin on Fri Dec 15 15:39:44 GMT 2023
PRIMARY